About 200 more drugs under price control

Earlier govt added 106 and removed 70 medicines from earlier one of 2011 expanding the list to 376 from 348

Image via Shutterstock
<a href="http://www.shutterstock.com/pic-86351161/stock-photo-many-pills-and-tablets-isolated-on-white-background.html" target="_blank">Image</a> via Shutterstock
BS Reporter New Delhi
Last Updated : Mar 15 2016 | 12:02 AM IST
The government has issued a new drug pricing control order which effectively brings close to 200 more drug formulations under regulation. In December 2015, while issuing a new National List of Essential Medicines (NLEM), the government had added 106 and removed 70 medicines from the earlier one of 2011, expanding the list to 376, from 348.

Based on the new NLEM, the government on Thursday notified the Drug (Price Control) Amendment Order, 2016. It has about 820 formulations. There were 628 formulations under the Drug Price Control Order (DPCO) of 2013, notified in the wake of the NLEM of 2011.

By law, the government has to issue a new price control order – and the National Pharmaceutical Pricing Authority (NPPA) needs to subsequently set their ceiling prices - whenever there is a new NLEM. The NPPA, say officials, would decide in two to three months. Currently, it has set the ceiling prices of 530 drugs of the 628 formulations in DPCO, 2013. Of the 530, a price reduction of above 40 per cent has happened in 126 medicines; those of another 34 have come down by 35-40 per cent.

“The regulator has reduced the price of 26 medicines by 30-35 per cent, while prices of 49 drugs have been reduced by 25-30 per cent,” said minister of state for chemicals Hansraj Ahir in a reply to a question in Parliament earlier this month.

While the prices of 65 medicines have been reduced by 20-25 per cent, 43 medicines have seen a cut of 15-20 per cent, he'd added.

NPPA is mandated to fix or revise prices of controlled bulk drugs and formulations, and to enforce prices and availability of medicines in the country, beside monitoring prices of decontrolled drugs, to keep these at reasonable levels.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 14 2016 | 11:58 PM IST

Next Story